---
document_datetime: 2025-12-29 13:13:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mepact.html
document_name: mepact.html
version: success
processing_time: 0.1142811
conversion_datetime: 2025-12-30 03:32:12.19978
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Mepact

[RSS](/en/individual-human-medicine.xml/65586)

##### Authorised

This medicine is authorised for use in the European Union

mifamurtide Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Mepact](#news-on)
- [More information on Mepact](#more-information-on-mepact-1019)
- [More information on Mepact](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Mepact. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Mepact.

Expand section

Collapse section

## What is Mepact?

Mepact is a powder that is made up into a suspension for infusion (drip into a vein). It contains the active substance mifamurtide.

## What is Mepact used for?

Mepact is used to treat high-grade non-metastatic osteosarcoma (a type of bone cancer) in patients aged between two and 30 years. 'High-grade' means that the cancer is of a severe type, and 'non-metastatic' means that it is at an early stage and has not spread far within the body. Mepact is used with other anticancer medicines after the cancer has been removed by surgery.

Because the number of patients with osteosarcoma is low, the disease is considered 'rare', and Mepact was designated an 'orphan medicine' (a medicine used in rare diseases) on 21 June 2004.

The medicine can only be obtained with a prescription.

## How is Mepact used?

Mepact treatment should be started and supervised by a specialised doctor who has experience in diagnosing and treating osteosarcoma.

The dose of Mepact depends on the patient's height and weight. It should be given twice a week for 12 weeks, and then once a week for 24 weeks. Mepact is given as a slow infusion lasting an hour. It must not be given as a bolus injection (all at once).

## How does Mepact work?

The active substance in Mepact, mifamurtide, is an immunomodulator. It works by activating macrophages and monocytes (types of white blood cell that form part of the immune system). The precise way that mifamurtide works in osteosarcoma is not fully understood, but it is thought to cause the white blood cells to release chemicals that kill the cancerous cells.

## How has Mepact been studied?

Mepact has been studied in one main study involving 678 patients aged between one and 31 years with high-grade non-metastatic osteosarcoma. After surgery to remove the cancer, all of the patients were given various combinations of anticancer medicines. Half of the patients were also given Mepact. The study compared patients who were given Mepact with those who were not. The main measure of effectiveness was the number of patients who survived without the disease coming back. The patients were followed up for up to 10 years.

## What benefit has Mepact shown during the studies?

Mepact, used with other anticancer medicines, increased how long patients survived without their disease coming back: 68% of the patients receiving Mepact (231 out of 338) survived without the disease coming back, compared with 61% of the patients who did not receive it (207 out of 340). The risk of dying was also reduced by 28% in patients receiving Mepact.

## What is the risk associated with Mepact?

The most common side effects with Mepact (seen in more than 1 patient in 10) are anaemia (low red-blood-cell counts), loss of appetite, headache, dizziness, tachycardia (rapid heartbeat), hypertension (high blood pressure), hypotension (low blood pressure), dyspnoea (difficulty breathing), tachypnoea (rapid breathing), cough, vomiting, diarrhoea, constipation, abdominal pain (stomach ache), nausea, hyperhidrosis (excessive sweating), myalgia (muscle pain), arthralgia (joint pain), back pain, pain in extremity (the arms and legs), fever, chills, fatigue (tiredness), hypothermia (low body temperature), general pain, malaise (feeling unwell), asthenia (weakness) and chest pain. For the full list of all side effects reported with Mepact, see the package leaflet.

Mepact should not be used in people who may be hypersensitive (allergic) to mifamurtide or any of the other ingredients. It must not be used at the same time as ciclosporin or other calcineurin inhibitors (medicines that reduce the activity of the immune system), or high doses of non-steroidal anti-inflammatory drugs (NSAIDs; used to treat pain and inflammation).

## Why has Mepact been approved?

The CHMP decided that Mepact's benefits are greater than its risks when used with other anticancer medicines and recommended that it be given marketing authorisation.

## Other information about Mepact

The European Commission granted a marketing authorisation valid throughout the European Union for Mepact on 6 March 2009. The marketing authorisation is valid for five years, after which it can be renewed.

For more information about treatment with Mepact, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Mepact : EPAR - Summary for the public

English (EN) (79.64 KB - PDF)

**First published:** 06/05/2009

**Last updated:** 01/10/2013

[View](/en/documents/overview/mepact-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-286)

български (BG) (128.75 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/bg/documents/overview/mepact-epar-summary-public_bg.pdf)

español (ES) (102.69 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/es/documents/overview/mepact-epar-summary-public_es.pdf)

čeština (CS) (128.27 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/cs/documents/overview/mepact-epar-summary-public_cs.pdf)

dansk (DA) (102.33 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/da/documents/overview/mepact-epar-summary-public_da.pdf)

Deutsch (DE) (103.29 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/de/documents/overview/mepact-epar-summary-public_de.pdf)

eesti keel (ET) (101.56 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/et/documents/overview/mepact-epar-summary-public_et.pdf)

ελληνικά (EL) (131.53 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/el/documents/overview/mepact-epar-summary-public_el.pdf)

français (FR) (102.96 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/fr/documents/overview/mepact-epar-summary-public_fr.pdf)

hrvatski (HR) (98.38 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/hr/documents/overview/mepact-epar-summary-public_hr.pdf)

italiano (IT) (102.86 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/it/documents/overview/mepact-epar-summary-public_it.pdf)

latviešu valoda (LV) (124.2 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/lv/documents/overview/mepact-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (125.53 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/lt/documents/overview/mepact-epar-summary-public_lt.pdf)

magyar (HU) (123.95 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/hu/documents/overview/mepact-epar-summary-public_hu.pdf)

Malti (MT) (191.63 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/mt/documents/overview/mepact-epar-summary-public_mt.pdf)

Nederlands (NL) (102.96 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/nl/documents/overview/mepact-epar-summary-public_nl.pdf)

polski (PL) (130.7 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/pl/documents/overview/mepact-epar-summary-public_pl.pdf)

português (PT) (104.01 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/pt/documents/overview/mepact-epar-summary-public_pt.pdf)

română (RO) (124.88 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/ro/documents/overview/mepact-epar-summary-public_ro.pdf)

slovenčina (SK) (127.44 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/sk/documents/overview/mepact-epar-summary-public_sk.pdf)

slovenščina (SL) (117.68 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/sl/documents/overview/mepact-epar-summary-public_sl.pdf)

Suomi (FI) (102.76 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/fi/documents/overview/mepact-epar-summary-public_fi.pdf)

svenska (SV) (102.66 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

01/10/2013

[View](/sv/documents/overview/mepact-epar-summary-public_sv.pdf)

## Product information

Mepact : EPAR - Product Information

English (EN) (561.29 KB - PDF)

**First published:** 06/05/2009

**Last updated:** 18/12/2025

[View](/en/documents/product-information/mepact-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-4)

български (BG) (630.46 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/bg/documents/product-information/mepact-epar-product-information_bg.pdf)

español (ES) (539.64 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/es/documents/product-information/mepact-epar-product-information_es.pdf)

čeština (CS) (580.24 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/cs/documents/product-information/mepact-epar-product-information_cs.pdf)

dansk (DA) (560.57 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/da/documents/product-information/mepact-epar-product-information_da.pdf)

Deutsch (DE) (818.88 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/de/documents/product-information/mepact-epar-product-information_de.pdf)

eesti keel (ET) (560.35 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/et/documents/product-information/mepact-epar-product-information_et.pdf)

ελληνικά (EL) (631.65 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/el/documents/product-information/mepact-epar-product-information_el.pdf)

français (FR) (521.67 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/fr/documents/product-information/mepact-epar-product-information_fr.pdf)

hrvatski (HR) (637.57 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/hr/documents/product-information/mepact-epar-product-information_hr.pdf)

íslenska (IS) (516.5 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/is/documents/product-information/mepact-epar-product-information_is.pdf)

italiano (IT) (512.03 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/it/documents/product-information/mepact-epar-product-information_it.pdf)

latviešu valoda (LV) (578.69 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/lv/documents/product-information/mepact-epar-product-information_lv.pdf)

lietuvių kalba (LT) (578.13 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/lt/documents/product-information/mepact-epar-product-information_lt.pdf)

magyar (HU) (579.15 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/hu/documents/product-information/mepact-epar-product-information_hu.pdf)

Malti (MT) (593.16 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/mt/documents/product-information/mepact-epar-product-information_mt.pdf)

Nederlands (NL) (507.2 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/nl/documents/product-information/mepact-epar-product-information_nl.pdf)

norsk (NO) (505.64 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/no/documents/product-information/mepact-epar-product-information_no.pdf)

polski (PL) (568.91 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/pl/documents/product-information/mepact-epar-product-information_pl.pdf)

português (PT) (517.02 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/pt/documents/product-information/mepact-epar-product-information_pt.pdf)

română (RO) (568.57 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/ro/documents/product-information/mepact-epar-product-information_ro.pdf)

slovenčina (SK) (626.1 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/sk/documents/product-information/mepact-epar-product-information_sk.pdf)

slovenščina (SL) (609.67 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/sl/documents/product-information/mepact-epar-product-information_sl.pdf)

Suomi (FI) (518 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/fi/documents/product-information/mepact-epar-product-information_fi.pdf)

svenska (SV) (568.93 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

18/12/2025

[View](/sv/documents/product-information/mepact-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000319446 18/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Mepact : EPAR - All Authorised presentations

English (EN) (15.64 KB - PDF)

**First published:** 06/05/2009

**Last updated:** 10/01/2014

[View](/en/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-575)

български (BG) (74.54 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/bg/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_bg.pdf)

español (ES) (24.67 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/es/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51.81 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/cs/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (23.78 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/da/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (24.5 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/de/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (15.25 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/et/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (52.09 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/el/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_el.pdf)

français (FR) (24.56 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/fr/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (47.11 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/hr/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (15.23 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/is/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_is.pdf)

italiano (IT) (24.75 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/it/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (51.18 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/lv/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (59.87 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/lt/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (50.8 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/hu/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (50.98 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/mt/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (24.6 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/nl/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (24.6 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/no/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_no.pdf)

polski (PL) (46.94 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/pl/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_pl.pdf)

português (PT) (24.34 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/pt/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_pt.pdf)

română (RO) (50.58 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/ro/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (52.16 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/sk/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (40.43 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/sl/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (24.77 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/fi/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.14 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

10/01/2014

[View](/sv/documents/all-authorised-presentations/mepact-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Mepact Active substance mifamurtide International non-proprietary name (INN) or common name mifamurtide Therapeutic area (MeSH) Osteosarcoma Anatomical therapeutic chemical (ATC) code L03AX15

### Pharmacotherapeutic group

Immunostimulants

### Therapeutic indication

Mepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with postoperative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients two to 30 years of age at initial diagnosis.

## Authorisation details

EMA product number EMEA/H/C/000802 Marketing authorisation holder

Esteve Pharmaceuticals, S.A.

Passeig de la Zona Franca, 109 Planta 4 08038 Barcelona Spain

Marketing authorisation issued 06/03/2009 Revision 22

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Mepact : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (151.91 KB - PDF)

**First published:** 17/07/2025

**Last updated:** 18/12/2025

[View](/en/documents/procedural-steps-after/mepact-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Mepact : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (184.19 KB - PDF)

**First published:** 26/02/2010

**Last updated:** 17/07/2025

[View](/en/documents/procedural-steps-after/mepact-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Mepact-H-C-PSUSA-00002059-201903 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/692996/2019

English (EN) (132.23 KB - PDF)

**First published:** 09/01/2020

[View](/en/documents/scientific-conclusion/mepact-h-c-psusa-00002059-201903-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Mepact-H-C-802-A20-22: EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/303390/2012

English (EN) (95.19 KB - PDF)

**First published:** 30/08/2012

**Last updated:** 30/08/2012

[View](/en/documents/variation-report/mepact-h-c-802-a20-22-epar-assessment-report-article-20_en.pdf)

## Initial marketing authorisation documents

Mepact : EPAR - Public assessment report

English (EN) (922.14 KB - PDF)

**First published:** 06/05/2009

**Last updated:** 06/05/2009

[View](/en/documents/assessment-report/mepact-epar-public-assessment-report_en.pdf)

#### News on Mepact

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-february-2012) 17/02/2012

[European Medicines Agency gives final recommendations for 12 centrally authorised medicines manufactured at Ben Venue Laboratories](/en/news/european-medicines-agency-gives-final-recommendations-12-centrally-authorised-medicines-manufactured-ben-venue-laboratories) 16/02/2012

[European Medicines Agency recommends precautionary recall of remaining batch of Vistide manufactured at Ben Venue Laboratories](/en/news/european-medicines-agency-recommends-precautionary-recall-remaining-batch-vistide-manufactured-ben-venue-laboratories) 13/12/2011

[European Medicines Agency gives further interim recommendations on dealing with shortcomings in quality assurance at Ben Venue Laboratories](/en/news/european-medicines-agency-gives-further-interim-recommendations-dealing-shortcomings-quality-assurance-ben-venue-laboratories) 09/12/2011

[European Medicines Agency gives interim recommendations to deal with shortcomings in quality assurance at Ben Venue Laboratories](/en/news/european-medicines-agency-gives-interim-recommendations-deal-shortcomings-quality-assurance-ben-venue-laboratories) 22/11/2011

#### More information on Mepact

Final recommendations on 12 centrally authorised medicines manufactured at Ben Venue Laboratories

Reference Number: EMA/106872/2012

English (EN) (188.14 KB - PDF)

**First published:** 16/02/2012

**Last updated:** 22/02/2012

[View](/en/documents/medicine-qa/final-recommendations-12-centrally-authorised-medicines-manufactured-ben-venue-laboratories_en.pdf)

Questions and answers on shortcomings in quality assurance at Ben Venue Laboratories

Reference Number: EMA/946321/2011

English (EN) (71.91 KB - PDF)

**First published:** 13/12/2011

**Last updated:** 13/12/2011

[View](/en/documents/medicine-qa/questions-and-answers-shortcomings-quality-assurance-ben-venue-laboratories_en.pdf)

This product is no longer an orphan medicine ( [EU/3/04/206](/en/medicines/human/orphan-designations/eu-3-04-206) ). It was originally designated an orphan medicine on 21 June 2004. Mepact was withdrawn from the Community register of orphan medicinal products in March 2019 at the end of the 10-year period of market exclusivity.

#### More information on Mepact

- [Mepact - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/mepact)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/12/2025

## Share this page

[Back to top](#main-content)